SCLERO.ORG
Search

Tracleer (Bosentan) by Actelion

Digital Ulcers, Pulmonary Fibrosis,
Pulmonary Hypertension (PH), Raynaud's, Scleroderma Renal Crisis, and Skin Fibrosis

Overview
Tracleer for Digital Ulcers
Tracleer for Pulmonary Fibrosis
Tracleer for Pulmonary Hypertension
Tracleer for Raynaud's
Tracleer for Scleroderma Renal Crisis
Tracleer for Skin Fibrosis
Also See

Overview

Tracleer® (bosentan) is made by Actelion Pharmaceuticals, Inc. The medication was initially developed for treatment of pulmonary hypertension, but has since proven useful in treating a variety of systemic scleroderma symptoms.

Tracleer (Bosentan) is proving useful for a variety of scleroderma symptoms, including pulmonary fibrosis, pulmonary hypertension, Raynaud's, and skin fibrosis. Bosentan is in a class of drugs called endothelin receptor antagonists by preventing an overproduction of endothelin.

Therefore, scleroderma researchers suggest that an early use of this drug should be considered for systemic scleroderma patients.

Tracleer (Bosentan) Drug Information including precautions, side effects and interactions. It may cause serious liver problems. Liver function should be monitored closely to decrease the risk of liver-related side effects. MedicineNet.

Tracleer (Bosentan) for Digital Ulcers

Tracleer is approved for the treatment of digital ulcers.

Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis (SSc). The study shows in patients with SSc with up to 4 years of combined therapy a progressive significant recovery in structure and function of microvasculature linked to improved clinical outcomes, independent of disease severity. PubMed, J Rheumatol, 2016 Nov;43(11):2033-2041. (Also see Treatment for Digital Ulcers: Iloprost)

Blood flow in the hands of a predefined homogeneous systemic sclerosis population: the presence of digital ulcers (DUs) and the improvement with bosentan. No relationship was found between blood flow in the hands and the presence of DUs. After 12 weeks of bosentan treatment, blood flow had increased in the SSc patients but had not normalized to that of healthy subjects. PubMed, Rheumatology (Oxford), 2015 Feb;54(2):262-9. (Also see Digital Ulcers)

Tracleer (Bosentan) for Heart Involvement in Systemic Sclerosis

Tracleer is approved for the treatment of pulmonary hypertension.

Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. Short-term treatment with bosentan simultaneously improves myocardial perfusion and function, as evaluated by highly sensitive and quantitative methods, in patients with SSc. Whether additional remodeling effect may be observed after longterm treatment with bosentan remains to be determined. J Rheumatol.

Tracleer (Bosentan) for Pulmonary Fibrosis (PF)

Tracleer is approved for the treatment of pulmonary hypertension.

Pulmonary (lung) fibrosis, is a scarring of the lungs, and is the consequence of untreated pulmonary inflammation (alveolitis). It is often also referred to as interstitial lung disease. ISN.

Tracleer (Bosentan) for Pulmonary Hypertension (PH, PAH)

Tracleer (Bosentan) is approved for the treatment of pulmonary hypertension.
The Actelion Pathways program is a free patient support program for people on Tracleer (Bosentan). It was formerly known as Sure Steps.

Actelion Pathways. We provide help getting started on your new treatment, programs to help you pay for your medicine, and information about specialty pharmacies and mail delivery. Actelion.

Bosentan and macitentan (ERA's) prevent the endothelial–to–mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. The present study provides further in vitro evidence of the use of ERA in inhibiting the EndoMT process, supporting the clinical efficacy of these drugs in SSc therapy and their usefulness for interfering with progressive fibrosis. PMC, Arthritis Res Ther, October 2016; 18: 228. (Also see Macitentan (Opsumit™) and Fibroblasts)

Beneficial effects of long–term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis. Long–term treatment with bosentan reduces the risk of developing PAH in patients with systemic sclerosis. PubMed, J Int Med Res, 2016 Sep;44(1 suppl):85-89.

Tracleer (Bosentan) for Raynaud's

Bosentan study for Raynaud's shows positive results.

Raynaud's is an extreme spasm of blood vessels in response to cold or stress. The fingers and/or toes become white and/or blue, and may become red on re-warming. (Also see Raynaud's Treatments)

Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis (SSc). Patients treated with Bosentan + Sildenafil show a significant improvement and this combination therapy may exert a vascular activity achieving an amelioration of the structure of microvasculature in SSc. PubMed, Clin Rheumatol, 12/03/2015. (Also see Raynaud's Treatments)

Bosentan for Scleroderma Renal Crisis

Clinical Trial in France

Effect of Bosentan in Scleroderma Renal Crisis (ScS-REINBO). This French clinical trial will be completed in June 2014. ClinicalTrials.gov.

Tracleer (Bosentan) for Systemic Scleroderma Skin Fibrosis

Tracleer study for systemic scleroderma skin fibrosis shows positive results.

Sclerodactyly by Sherrill KnaggsSkin fibrosis is a process that follows chronic inflammation. Fibrotic tissue is like a scar tissue, thick, and rigid, due to an excess accumulation of protein below the skin. The diagnosis is clinical, and requires no laboratory or special testing. (Photo: Sclerodactyly, the culminating result of fibrosis affecting the hands of a systemic scleroderma patient.)

Also See

Digital Ulcers

Pulmonary Fibrosis

Pulmonary Hypertension

Raynaud's Treatments

Scleroderma Medical News

Systemic Scleroderma Symptoms (Main list; treatments are listed on each symptom page.)

Scleroderma Treatments and Clinical Trials

Skin Fibrosis

Go to Scleroderma Clinical Trials: Stem Cell Transplants
 

See ISN News for recent donors. Click Here to Donate.

 

TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.

We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, report bad links, or update page content. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!